By a News Reporter-Staff News Editor at Biotech Week -- New research on Drugs and Therapies is the subject of a report. According to news reporting out of Turin, Italy, by NewsRx editors, research stated, "Pharmaceutical technology has introduced a promising pathway in the future of medicine in particular nanotechnological innovations have provided the opportunity to design and develop efficient drug delivery systems able to target and treat several diseases, including those mediated by inflammation. The engineering of drug delivery systems can be used to target tissues involved in the pathology under treatment, to avoid early drug biological environmental degradation and to modulate drug pharmacokinetics."
Our news journalists obtained a quote from the research from the University of Turin, "Glucocorticoids and non-steroidal anti-inflammatory drugs are the most commonly prescribed drug categories worldwide for the treatment of disorders associated with inflammation. Although glucocorticoids can be highly effective in treating inflammation, their systemic application is limited due to the high incidence of serious adverse effects, mainly in long-term treatment. Non-steroidal anti-inflammatory drugs are a heterogeneous group of compounds and most of them have unfavorable pharmacokinetics and pharmacodynamics, leading to adverse effects, such as gastrointestinal disorders. Therefore, the need for drug delivery systems for long term administration of anti-inflammatory drugs with a well-controlled release profile is evident."
According to the news editors, the research concluded: "The aim of this review is to assess innovative colloidal drugs carriers, in particular liposomes and nanoparticles, with special focus on site-specific delivery for particularly problematic tissues such as the gastrointestinal tract, joints and eyes."
For more information on this research see: Innovative Formulations for the Controlled and Site-specific Delivery of Anti-inflammatory Drugs. Current Pharmaceutical Design, 2013;19(41):7219-7236. Current Pharmaceutical Design can be contacted at: Bentham Science Publ Ltd, Executive Ste Y-2, PO Box 7917, Saif Zone, 1200 Br Sharjah, U Arab Emirates. (Bentham Science Publishers - www.benthamscience.com; Current Pharmaceutical Design - www.benthamscience.com/cpd/index.htm)
Our news journalists report that additional information may be obtained by contacting L. Serpe, University of Turin, Dept. of Drug Sci & Technol, I-10125 Turin, Italy. Additional authors for this research include R. Canaparo, F. Foglietta and G.P. Zara (see also Drugs and Therapies).
Keywords for this news article include: Turin, Italy, Europe, Treatment, Inflammation, Drugs and Therapies, Drug Delivery Systems
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC